ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1142

The Lupus Risk Allele Associated Xq28 Haplotype Identifies the Molecular Endotype of a Cohort of European SLE Patients with Enhanced IRAK1 Signaling

Rheyanna Clemens1, Tyson Dawson1, Katherine Owen2, Amrie Grammer3 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2RILITE, Crozet, VA, 3AMPEL LLC, Charlottesville, VA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Gene Expression, genetics, innate immunity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Genetics, Genomics and Proteomics Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Previous genetic association studies identified a 9 gene region of Xq28 containing IRAK1 as a risk locus for SLE. IRAK1 plays key roles downstream of the endosomal TLRs and IL-1 receptors to activate NF-KB during inflammatory responses. While single nucleotide polymorphisms (SNPs) in IRAK1 have been independently associated with SLE risk, the molecular pathways have not fully delineated the differential impact in lupus patients of different ancestries. Here, we provide a full characterization of the genetic haplotype predictive of a patient endotype characterized by enhanced IRAK1 signaling in European ancestry SLE patients.

Methods: Gene Analysis Tool Kit variant calling was used to identify expression of 150 known Xq28 SNPs in an RNA-seq dataset of SLE patients of European (EA) or Asian (AsA) ancestry. Patient cohorts were determined by SNP expression and visualized via t-SNE plot. Differentially expressed gene (DEG) datasets were created to leverage inter-cohort and intra-ancestral changes in gene expression. DEGs were integrated into protein-protein interaction networks, partitioned with MCODE, and annotated using a variety of bioinformatics tools. Gene set enrichment analysis (GSEA) was utilized to validate overall enrichment of pathways observed with MCODE clustering. For comparison, DEGs derived from IRAK1/2-deficient mice (GSE10765) were clustered and annotated to identify pathways down-regulated in the absence of IRAK1.

Results: Variant calling detected 150 SNPs in the Xq28 region from SLE patients with approximately 33% total coverage. 4 independent cohorts based on SNP expression were grouped by t-SNE. Cohorts 1 and 2 comprised 45% and 33% of subjects, respectively, with cohort 1 being 90% AsA ancestry (AsA-1) and cohort 2 being 90% EA ancestry (EA-2). The AsA-1 haplotype expressed primarily homozygous alternate alleles within AVPR2–TMEM187 and reference alleles elsewhere, whereas the EA-2 haplotype expressed alternative alleles within IRAK1–MECP2 (Figure 1). The smaller cohorts 3 and 4 comprised 21% of all subjects and expressed heterozygous SNPs across the entire region in both ancestries. Pathway analysis of EA-2 DEGs indicated activation of innate and inflammatory immune responses related to TLR signaling that are consistent with IRAK1 up-regulation in this patient cohort. In contrast, AsA-1 had no enrichment of similar pathways. Using the IRAK1/2 KO mouse as reference, we further confirmed that genes down-regulated in the absence of IRAK1 are strong predictors of genes up-regulated in SLE patients of EA ancestry harboring the IRAK1 variant risk allele.

Conclusion: Here, we confirmed expression of previously documented SNPs in Xq28 in SLE patients and discovered 2 distinct haplotypes indicative of patient ancestry. We observed and validated up-regulation of inflammatory pathways downstream of TLR signaling in EA patients expressing alternate alleles in the IRAK1 locus, confirming IRAK1 as a disease-associated gene in these patients. Modulation of IRAK1 signaling could serve as a target for the abrogation of inflammation, predominantly in SLE patients of EA ancestry.

Supporting image 1

Figure 1: SNP expression, detection and cohort separation annotated with size and ancestral make-up of 4 independent cohorts determined by t-SNE.


Disclosures: R. Clemens, None; T. Dawson, None; K. Owen, None; A. Grammer, None; P. Lipsky, None.

To cite this abstract in AMA style:

Clemens R, Dawson T, Owen K, Grammer A, Lipsky P. The Lupus Risk Allele Associated Xq28 Haplotype Identifies the Molecular Endotype of a Cohort of European SLE Patients with Enhanced IRAK1 Signaling [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-lupus-risk-allele-associated-xq28-haplotype-identifies-the-molecular-endotype-of-a-cohort-of-european-sle-patients-with-enhanced-irak1-signaling/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-lupus-risk-allele-associated-xq28-haplotype-identifies-the-molecular-endotype-of-a-cohort-of-european-sle-patients-with-enhanced-irak1-signaling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology